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T he diagnosis and management of multiple myeloma were reviewed earlier in this Symposium on Oncology Practice: Hematological Malignancies. 1 This review focuses on the current diagnosis and management of other related clonal plasma cell disorders (Table 1 ). This list is diverse and includes the relatively common premalignant condition monoclonal gammopathy of undetermined significance (MGUS), as well as uncommon disorders such as POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome.
MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE
MGUS is an asymptomatic premalignant disorder characterized by limited monoclonal plasma cell proliferation in the bone marrow and absence of end-organ damage. 10, 12 It is the most common plasma cell dyscrasia, prevalent in approximately 3% of the general population aged 50 years and older. 13 The prevalence increases with age: 1.7% in those 50 to 59 years of age and more than 5% in those older than 70 years. Within each age group, prevalence rates are higher in men than in women. The age-adjusted prevalence of MGUS is 3-fold higher in African Americans compared with white persons. 14 MGUS is associated with a lifelong risk of progression to multiple myeloma or related disorders. The rate of progression of MGUS to multiple myeloma or related malignancy is 1% per year ( Figure 1) . 4, 15 However, the true lifetime probability of progression is substantially lower when competing causes of death are taken into account, approximately 11% at 25 years ( Figure 1 ). 16 The risk of progression with MGUS does not diminish with time, making lifelong follow-up necessary in all persons. 4, 17 In fact, the risk of progression remains constant regardless of duration of known MGUS, strongly suggestive of a random 2-hit model of malignant progression, rather than a cumulative damage model in which case the risk of progression will be expected to rise with the duration of the abnormality. 12 MGUS is characterized by evidence of genomic instability on molecular genetic testing: primary chromosomal translocations at the immunoglobulin heavy chain locus 14q32 (50%), hyperdiploidy (40%), or other or unknown (10%).
12,18-23 Interleukin 6 is a major growth factor for plasma cells, 24 and CD126 (interleukin 6 receptor α-chain) is overexpressed in MGUS compared with normal plasma cells. 25, 26 A significantly higher proportion of plasma cells express CD45 in the MGUS stage compared with multiple myeloma. 27 Recent advances in the pathogenesis and progression of MGUS have been reviewed earlier in this series.
DIAGNOSIS
The diagnostic criteria for MGUS are listed in Table 1.   2,3 MGUS is differentiated from multiple myeloma and related disorders based on the presence or absence of endorgan damage that can be attributed to the plasma cell disorder. The differentiation of MGUS from multiple myeloma or other related disorders can be difficult at the time of initial presentation because MGUS is relatively common in the general population older than 50 years, and a number of clinical and laboratory abnormalities may be coincidental. The typical laboratory investigations necessary to differentiate MGUS from other related plasma cell disorders are a complete blood cell count, serum creatinine measurement, serum calcium measurement, and a com- POEMS syndrome Presence of a monoclonal plasma cell disorder, peripheral neuropathy, and at least 1 of the following 7 11 features: osteosclerotic myeloma, Castleman disease, organomegaly, endocrinopathy (excluding diabetes mellitus or hypothyroidism), edema, typical skin changes, and papilledema. Note: Not every patient who meets these criteria will have POEMS syndrome; the features should have a temporal relationship to each other and no other attributable cause. The absence of either osteosclerotic myeloma or Castleman disease should make the diagnosis suspect. Elevations in plasma or serum levels of vascular endothelial growth factor and thrombocytosis are common features of the syndrome and are helpful when the diagnosis is difficult.
*MGUS = monoclonal gammopathy of undetermined significance; MRI = magnetic resonance imaging; SMM = smoldering multiple myeloma.
plete radiographic bone survey. If abnormalities are detected on these tests, additional tests to determine the cause of these abnormalities are required; only patients in whom abnormalities are believed to be related to the plasma cell proliferative disorder can be considered to have myeloma or related malignancy. A bone marrow aspirate and biopsy are indicated when the M protein level is greater than or equal to 1.5 g/dL and when abnormalities are noted in the complete blood cell count, serum creatinine level, serum calcium level, or radiographic bone survey. Bone marrow aspirate and biopsy should also be considered in patients with non-IgG MGUS, patients with an abnormal serum free light chain (FLC) ratio, and any other patient with presumed MGUS in whom there is doubt about the diagnosis.
PROGNOSIS
In a large population-based study of MGUS that involved 1384 patients, only the size and type of M protein (IgM and IgA subtypes) were predictive of progression to myeloma or related malignancy. 4 In another study, a bone marrow plasma cell percentage of 6% to 9% carried twice the risk of progression compared with marrow involvement of 5% or lower. 28 The presence of circulating plasma cells detected using a sensitive slide-based immunofluorescent assay is also a risk factor for progression, 29 but the test is not widely available in clinical practice.
An abnormal serum FLC ratio using the serum FLC assay is an important risk factor for progression of MGUS. In a study of 1148 patients, the risk of progression with an abnormal FLC ratio at the time of diagnosis of MGUS was significantly higher compared with a normal ratio (hazard ratio, 3.5; 95% confidence interval, 2.3-5.5; P<.001) and was independent of the size and type of the serum M protein. 16 The risk of progression to myeloma or related malignancy at 10 years was 17% with an abnormal ratio compared with 5% with a normal ratio.
A risk stratification system can be used to predict the risk of progression of MGUS based on 3 factors: size of the serum M protein, the type of immunoglobulin, and the serum FLC ratio (Table 2) . 16 Patients with 3 adverse risk factors, namely, an abnormal serum FLC ratio, non-IgG MGUS, and a high serum M protein level (≥15 g/L), had a risk of progression at 20 years of 58% (high-risk MGUS) compared with 37% in patients with any 2 of these risk factors present (high-to intermediate-risk MGUS), 21% with 1 risk factor present (low-to intermediate-risk MGUS), and 5% when none of the risk factors were present (low-risk MGUS). In fact, the low-risk MGUS subset (constituting almost 40% of the cohort) had a lifetime risk of only 2% when competing causes of death were taken into account.
TREATMENT
The current standard of care for MGUS is observation alone, without therapy. 30, 31 Patients with MGUS may benefit from risk stratification to guide follow-up. Patients with low-risk MGUS can be reassessed in 6 months and then once every 2 years or only at the time of symptoms for evidence of progression. 16 All other subsets of patients need to be reassessed in 6 months and then yearly thereafter.
SMOLDERING MULTIPLE MYELOMA
Smoldering multiple myeloma (SMM) accounts for approximately 15% of all cases with newly diagnosed multiple myeloma. 9, 10 The prevalence estimates for SMM are unreliable since some studies include asymptomatic patients with small lytic bone lesions on skeletal survey and/ or abnormalities on magnetic resonance imaging (MRI). Similar to MGUS, SMM is an asymptomatic condition. However, the risk of progression to myeloma or related malignancy is much higher in SMM compared with MGUS: 1% per year vs 10% to 20% per year, respectively. 4, 15, 32, 33 This difference in the risk of progression means that patients with SMM and MGUS should be managed differently in terms of frequency of follow-up, development of chemopreventive strategies, and enrollment into clinical trials. Similar to patients with MGUS and active myeloma, almost all patients with SMM appear to have evidence of genomic instability manifested as IgH translocations or hyperdiploidy on molecular genetic testing. 34 Most patients with SMM eventually experience progression to symptomatic disease 9 ; however, some patients can remain free of progression for a number of years. 35 The time to progression (TTP) to symptomatic disease is approximately 3 to 4 years but differs greatly depending on the definition used for SMM. 33 In the subset of SMM patients with 10% or more bone marrow plasma cells, the median TTP is approximately 2 to 3 years. 36 Preliminary data from a large study by Kyle et al 37 using the current criteria for SMM estimate the risk of progression at approximately 10% per year for the first 5 years, a rate much higher than that observed with MGUS.
DIAGNOSIS
Smoldering multiple myeloma is asymptomatic. The diagnosis requires the presence of a serum IgG or IgA M protein level of 3 g/dL or higher and/or 10% or more bone marrow plasma cells, plus absence of anemia, hypercalcemia, lytic bone lesions, or renal failure that can be attributed to the plasma cell proliferative disorder (Table 1) . 2, 3 Testing to differentiate SMM from multiple myeloma is the same as that described for MGUS.
PROGNOSIS
Similar to results in MGUS, abnormal peripheral blood monoclonal plasma cell studies, defined as an increase in the number or proliferative rate of circulating plasma cells by slide-based immunofluorescent assays, have been shown to indicate a higher risk of progression in SMM. 36 However, this test is not widely available in clinical practice. Weber et al 32 have shown that, similar to MGUS, the size and type of immunoglobulin are important predictors of progression in SMM (Table 3) .
The presence of occult bone lesions on MRI increases the risk of progression in patients otherwise defined as having SMM. 9 In a recent study, Wang et al 33 estimated the risk of progression in 72 patients with SMM in whom an MRI of the spine was also performed. The median TTP was significantly shorter with an abnormal MRI result compared with a normal MRI result (1.5 years vs 5 years, respectively).
TREATMENT
The standard of care is observation alone until evidence of progression to myeloma. 30 Patients with SMM need more frequent follow-up than those with MGUS (at least every 3 to 4 months). 12 Two small randomized trials have shown no benefit with early therapy compared with therapy at the time of symptomatic progression. 38, 39 Preliminary data indicate that thalidomide may delay TTP, 40, 41 but data are needed from randomized trials before such therapy can be recommended, particularly given the adverse effects associated with the drug. With the increasing availability of novel targeted therapies for myeloma, [42] [43] [44] clinical trials are ongoing to determine whether the early use of new agents or bisphosphonates can delay progression in SMM.
WALDENSTRÖM MACROGLOBULINEMIA
Waldenström macroglobulinemia is a clonal IgM monoclonal protein-secreting lymphoid and plasma cell disorder, which currently also includes the entity referred to previously as lymphoplasmacytic lymphoma. The median age at diagnosis is approximately 65 years, with a slight male predisposition. The typical symptoms at presentation are weakness and fatigue due to anemia. Other clinical manifestations may include constitutional symptoms (fever, night sweats, and weight loss), hepatosplenomegaly, lymphadenopathy, hyperviscosity, cryoglobulinemia, and sensorimotor peripheral neuropathy. 45 Unlike multiple myeloma, primary IgH translocations are not seen in Waldenström macroglobulinemia. 46 
DIAGNOSIS
The diagnostic criteria for Waldenström macroglobulinemia are listed in Table 1 . The Second International Consensus Panel did not assign a specific level of bone marrow infiltration that would be required to differentiate IgM MGUS from Waldenström macroglobulinemia. 5 The diag- nostic criteria given in Table 1 have been updated in an evidence-based manner such that the diagnosis of Waldenström macroglobulinemia requires 10% or greater lymphoplasmacytic infiltration. 4, [6] [7] [8] Presence of less than 10% lymphoplasmacytic infiltration in the absence of end-organ damage represents IgM MGUS and not Waldenström macroglobulinemia; such patients have a risk of progression to symptomatic disease at a rate of only 1.5% per year. 6 In fact, patients with IgM MGUS and smoldering Waldenström macroglobulinemia, as defined using the criteria in Table 1 , have an overall survival rate similar to (perhaps even better than in the case of IgM MGUS) the general population and should not be considered to have malignant disease. 7 Historically, patients with an IgM M protein level less than 3 g/dL who met the criteria for Waldenström macroglobulinemia have been classified as having "lymphoplasmacytic lymphoma with an IgM M protein." However, except for hyperviscosity, the clinical picture, therapy, and prognosis in these patients are no different than in those patients classified as having Waldenström macroglobulinemia who have an IgM M protein level of 3 g/dL or higher. 47 By the current definition, patients are considered to have Waldenström macroglobulinemia regardless of the size of the serum M protein.
PROGNOSIS
The median survival is approximately 5 years. 45 Adverse prognostic factors include age older than 70 years, hemoglobin level less than 9 g/dL, weight loss, and cryoglobulinemia. 48 Morel et al 49 have constructed a risk stratification model based on a set of 3 adverse prognostic factors: age 65 years or older, albumin level less than 4.0 g/dL, and cytopenias (Table 4) .
TREATMENT
As with SMM, patients who meet the diagnostic criteria for Waldenström macroglobulinemia who are asymptomatic may also be considered to have smoldering Waldenström macroglobulinemia and have no need of immediate therapy. The indications for therapy are anemia (hemoglobin level <10 g/dL) or thrombocytopenia (platelet count <100 × 10 9 /L) believed to be related to Waldenström macroglobulinemia; constitutional symptoms such as weakness, fatigue, night sweats, or weight loss; hyperviscosity; symptomatic cryoglobulinemia; and significant hepatosplenomegaly or lymphadenopathy. 45, 50, 51 INITIAL THERAPY There are 4 options for initial therapy: rituximab, purine nucleoside analogues, alkylators, and combination chemotherapy. Unfortunately, no randomized data exist to determine the best option; therapy is typically decided based on the age of the patient and the aggressiveness of the presentation. Patients should preferably be treated in clinical trials as much as possible.
Single-agent therapy with rituximab, a chimeric anti-CD20 monoclonal antibody, produces a response in approximately 50% of untreated patients. 52, 53 Response to rituximab may be affected by polymorphisms in the Fc-γ RIIIA (CD16) receptor gene. 54 Responses to rituximab can be delayed and may occur months after initial therapy. An initial increase in IgM levels (flare) has been reported. 55 The usual dose is 375 mg/m 2 administered intravenously weekly for 4 weeks, 53 with consideration given to further doses or maintenance, depending on response.
Purine nucleoside analogues, fludarabine or cladribine, are also effective as initial therapy. [56] [57] [58] [59] [60] [61] Reported response rates vary widely from 40% to 90% and likely reflect patient selection and the stringency and timing of the response assessment. Both agents are likely equally effective; randomized comparisons have not been conducted. We prefer a cladribine dosage of 5 mg/m 2 intravenously over 2 hours for 5 days, repeated once after 28 days if needed. The need for further cycles is determined by the extent of response to the first 2 cycles and observed toxic effects.
Alkylators such as chlorambucil are an option, especially for elderly patients, as initial therapy. Chlorambucil is administered orally at a dosage of 6 to 8 mg/d with dose adjustments based on blood cell counts. Patients are treated until the disease has reached a plateau state; treatment can then be discontinued and patients observed closely.
Preliminary results of several combination chemotherapeutic approaches have been reported, with response rates of more than 75%. 50 Examples of active combinations include fludarabine plus rituximab, fludarabine plus cyclophosphamide, cladribine plus cyclophosphamide plus rituximab, and R-CHOP (rituximab, cyclophosphamide, hydroxydaunomycin (doxorubicin), vincristine (Oncovin), prednisone). 51, 62 Our preferred approach outside a clinical trial setting is to use single-agent therapy in most patients, reserving combination therapy for aggressive disease.
RELAPSED DISEASE AND SUPPORTIVE CARE
The options for initial therapy can be tried at the time of relapse. In fact, the same initial therapy can be tried again at relapse if there was an adequate interval between cessation of therapy and relapse. A response rate of 25% has been reported with single-agent thalidomide. 63 Other options for relapsed, refractory disease include stem cell transplantation, 64 interferon alfa, 65, 66 and bortezomib. 67 Novel agents are also being investigated. 68 A small subset of chemotherapy-resistant patients may respond to splenectomy. 51 Patients with refractory anemia or anemia during chemotherapy will benefit from erythropoietin and/or red blood cell transfusions. Plasmapheresis is indicated for the treatment of hyperviscosity syndrome. 51 Plasmapheresis may need to be continued intermittently until a therapeutic response is achieved with one of the treatment options discussed herein.
SYSTEMIC AL (IMMUNOGLOBULIN LIGHT CHAIN) AMYLOIDOSIS
Amyloid is a fibrillar proteinaceous material that can be deposited in various tissues and detected with Congo red staining based on a characteristic apple-green birefringence under polarized light. 69 It consists of rigid, linear, nonbranching fibrils, 7.5 to 10 nm in width, aggregated in a β-pleated sheet conformation. Several distinct types of amyloidosis have been classified based on the protein composition of the amyloid material (Table 5) .
AL (immunoglobulin light chain) amyloidosis refers to the type of amyloidosis derived from the variable portion of a monoclonal light chain or, in rare instances, intact monoclonal light chain and occurs as a result of a clonal plasma cell proliferative disorder. 70 AL amyloidosis may be localized (a benign disorder) or systemic. Systemic AL amyloidosis has been commonly referred to as primary systemic amyloidosis or, simply, primary amyloidosis.
The pathogenesis of AL amyloidosis is not well understood. It involves aberrant de novo synthesis and abnormal proteolytic processing of light chains. The catabolism of amyloid fibrils may also play a role. IgH translocations have been reported in more than 70% of patients with systemic AL amyloidosis. 71 A distinct gene expression profile also appears to be associated with AL amyloidosis compared with myeloma; a set of 12 genes was recently found to discriminate between AL amyloidosis and multiple myeloma with more than 85% accuracy on gene expression profiling studies. 72 Certain germline immunoglobulin light chain V genes, 6a V λVI and 3r V λIII , code for the monoclonal light chain regions involved in systemic AL amyloidosis in approximately 40% of patients. 73 Studies show that the nature of organ involvement in AL amyloidosis is related to which of the various immunoglobulin light chain germline V genes the plasma cell clone is derived from. 74, 75 Patients with clones derived from the 6a V λVI germline light chain gene have a greater likelihood of dominant renal amyloidosis. In contrast, patients with clones derived from the 1c, 2a2, and 3r V λ genes are more likely to present with dominant cardiac and multisystem amyloidosis.
DIAGNOSIS
The diagnosis of systemic AL amyloidosis requires documentation of positive amyloid staining on a tissue biopsy and supporting evidence that the amyloid is derived from immunoglobulin light chains (Table 1) . This condition should be suspected when patients with the appropriate clinical syndrome (eg, nephrotic syndrome, axonal neuropathy, restrictive cardiomyopathy) display evidence of a plasma cell proliferative disorder, such as a serum or urine monoclonal protein.
Systemic AL amyloidosis should be differentiated from localized amyloidosis, which can be derived from immunoglobulin light chains in many patients (localized AL amyloidosis). 69 Localized amyloidosis is typically benign and can manifest as isolated carpal tunnel syndrome; isolated lesions in the ureter, urethra, bladder, lung, bronchus, or trachea; or nonpurpuric cutaneous lesions. Localized amyloidosis, regardless of whether the source of the amyloid is immunoglobulin light chain or some other protein, is treated primarily for symptom relief as needed and should not be treated with systemic therapy.
The median age at diagnosis of systemic AL amyloidosis is 65 years. The clinical manifestations vary greatly and depend on the dominant organ involved. Nephrotic syndrome, restrictive cardiomyopathy, and peripheral or autonomic neuropathy are common presenting syndromes. Patients may also have associated macroglossia, carpal tunnel syndrome, and purpura that involve the neck, face, and eyes. Immunofixation reveals an M protein in the serum or urine in approximately 90% of patients at diagnosis. The FLC ratio is abnormal in most of the patients with a negative immunofixation. Regardless of the number of plasma cells in the bone marrow, the syndrome is referred to as AL or primary as long as the amyloid fibrils are composed of immunoglobulin light chain. Systemic AL amyloidosis and symptomatic multiple myeloma can coexist in the same patient, but usually 1 of the 2 disorders dominates the clinical picture.
PROGNOSIS
Survival varies greatly, depending on the dominant organ involved (with cardiac amyloid having the worst outcome) and the number of affective major organs. 69, 76 Patients ineligible for stem cell transplantation have an estimated median survival of 18 months compared with more than 40 months for those eligible for transplantation. 76 Elevated levels of cardiac troponin T carry an adverse prognosis. Median survival for patients with detectable cardiac troponin T (≥1 µg/L) is significantly shorter than for those with undetectable levels (6 vs 22 months, respectively). 77 Elevated serum cardiac troponin I and N-terminal pro-brain natriuretic peptide levels are also valuable prognostic markers. 77, 78 A risk stratification model using the cardiac troponin T and N-terminal pro-brain natriuretic peptide levels is given in Table 6 . 79, 80 TREATMENT Response to therapy in AL amyloidosis can be difficult to assess. Specific response criteria to assess hematologic and organ responses in primary amyloidosis were recently published. 81 Melphalan and prednisone have been the mainstay of treatment for many years, but results are unsatisfactory. 82 Currently, our approach is to stratify patients based on eligibility for stem cell transplantation. Patients ineligible for stem cell transplantation (poor performance status, major comorbidities, 3 or more organs involved, and advanced cardiac amyloidosis) are offered therapy in clinical trials or treatment with melphalan plus high-dose dexamethasone. 83 Melphalan is administered at a dosage of 0.22 mg/kg per day orally on days 1 through 4 with high-dose dexamethasone, 40 mg/d orally, on the same 4 days. Cycles are repeated every 28 days for approximately 9 months. Using this regimen, a hematologic response was noted in 67% of patients in one trial, with 33% achieving complete hematologic remission. 84 Improvement in organ function is seen in approximately 50% of responding patients. Prolonged and impressive organ remissions can be achieved with autologous stem cell transplantation in approximately 50% of patients treated with such therapy. [85] [86] [87] [88] However, preliminary results of a French randomized trial suggest that overall survival may not be superior with stem cell transplantation compared with melphalan plus highdose dexamethasone. 89 This trial randomized 100 patients; median actuarial survival was 57 months with melphalan plus high-dose dexamethasone and 49 months with transplantation (P=.20). However, interpretation of this trial is confounded by the relatively short follow-up (29 months) and the very high treatment-related mortality observed in the transplantation arm (24%). It is wise to consider enrollment in ongoing clinical trials that compare the 2 approaches. At Mayo Clinic, a randomized trial is ongoing that compares autologous stem cell transplantation vs melphalan plus high-dose dexamethasone. For selected candidates, autologous stem cell transplantation is appropriate as initial therapy but is better performed at specialized centers since, unlike with transplantations for myeloma, treatment-related mortality is high (approximately 13%). In patients who proceed to early transplantation, there does not appear to be any need for induction therapy. 90 Excessive fluid accumulation during stem cell mobilization (>2% weight gain) is predictive of a higher mortality rate with stem cell transplantation. 91 The typical conditioning regimen used is high-dose intravenous melphalan (100-200 mg/m 2 ) with the exact dose level based on age, presence or absence of cardiac involvement, number of organs involved, and creatinine clearance. 83 Highly selected patients with endstage amyloid renal disease and end-stage amyloid cardiomyopathy have been considered for sequential kidney stem cell transplantation and sequential cardiac stem cell transplantation, respectively. 92, 93 A recent study found that thalidomide plus dexamethasone may be a second-line treatment option for patients with systemic AL amyloidosis, with hematologic responses seen in 48% of 31 enrolled patients, including complete responses in 19% and organ responses in 26%. 94 However, thalidomide is less well tolerated in amyloidosis compared with myeloma, 95 and the regimen is associated with significant adverse effects. Lenalidomide, an analogue of thalidomide with lesser toxicity, may have activity in AL amyloidosis, but further studies are needed. 96 Patients with amyloidosis also require significant supportive care based on the nature of organ involvement, such as treatment of nephrotic syndrome, malabsorption, neuropathy, and heart failure.
SOLITARY PLASMACYTOMA
Solitary plasmacytomas may be confined to bone (solitary bone plasmacytoma) or occur in extramedullary sites (extramedullary plasmacytoma). 97 Extramedullary plasmacytoma is localized to the upper respiratory tract (nasal cavity and sinuses, nasopharynx, and larynx) in more than 80% of cases but can also occur in the gastrointestinal tract, central nervous system, urinary bladder, thyroid, breast, testes, parotid gland, or lymph nodes. Patients with solitary plasmacytoma are at risk of progression to multiple myeloma. Increased microvessel density detected in the initial diagnostic tissue specimen has been associated with an increased risk of progression to multiple myeloma, suggesting that the evolution to systemic disease may depend on an angiogenic switch. 98 DIAGNOSIS AND PROGNOSIS Diagnostic criteria are listed in Table 1 . An MRI of the spine and pelvis should be performed in addition to a skeletal survey, since approximately one third of patients may have additional occult lesions that will be missed in the absence of an MRI.
99
Patients with a baseline serum M protein greater than 1 g/dL have a high risk of persistence of an M protein after radiation therapy to the involved site. 100 Persistence of an M protein 1 year or more after radiation therapy has been associated with an increased probability of progression to multiple myeloma in patients with solitary bone plasmacytoma. 101 The 10-year myeloma-free survival was 29% in patients with a persistent serum or urinary M protein compared with 91% in those in whom the M protein was not detectable after radiation therapy.
TREATMENT Treatment consists of radiation in the range of 40 to 50 Gy to the involved site. 9 Patients who meet criteria for solitary plasmacytoma except for evidence of clonal involvement of the bone marrow can be also treated with radiation therapy to the involved site and then observed until disease progression, similar to MGUS (<10% bone marrow plasma cells) or SMM (≥10% plasma cells).
More than 50% of patients with a solitary bone plasmacytoma are alive at 10 years, 101 and disease-free survival at 10 years ranges from 25% to 50%. 97 Progression to myeloma, when it occurs, usually occurs within 3 years, but patients must be followed up indefinitely. Prognosis may be better in patients with solitary extramedullary plasmacytoma, with 10-year disease-free survival rates of approximately 70% to 80%. 97 
POEMS SYNDROME
POEMS syndrome is a rare, atypical plasma cell proliferative disorder. It has been variously referred to in the literature as osteosclerotic myeloma, Crow-Fukase syndrome, PEP (plasma cell dyscrasia, endocrinopathy, polyneuropathy) syndrome, and Takatsuki syndrome. In almost all cases the immunoglobulin light chain type in POEMS syndrome is λ.
DIAGNOSIS
The median age at presentation is 51 years. POEMS syndrome is defined by the criteria listed in Table 1. 11 Almost all patients with POEMS syndrome have either osteosclerotic lesions or Castleman disease. The major clinical features of POEMS syndrome are a predominantly motor chronic inflammatory demyelinating polyneuropathy, sclerotic bone lesions, and a varying number of associated abnormalities, such as hepatomegaly, hyperpigmentation, hypertrichosis, gynecomastia, testicular atrophy, clubbing, polycythemia, thrombocytosis, and Castleman disease. Patients may have respiratory problems that range from neuromuscular weakness to reduced diffusion capacity of carbon monoxide to pulmonary hypertension. Biopsy of an osteosclerotic lesion may be necessary for the diagnosis. The pathogenesis of the syndrome is unclear but appears to be at least in part cytokine mediated, and elevated vascular endothelial growth factor levels are commonly found. 102, 103 PROGNOSIS AND TREATMENT POEMS syndrome may have an indolent or a fulminant course. In one study of 99 patients, median survival was 13.8 years. 104 If unchecked, the clinical course is characterized by progressive disabling neuropathy, inanition, anasarca, and pulmonary demise. The number of features involved is not predictive of survival, but the presence of fingernail clubbing or extravascular volume overload is predictive.
The clinical features of patients with POEMS syndrome are distinct from those with classic multiple myeloma. In POEMS syndrome, progressive anemia and bone pain are unusual. When renal failure occurs in POEMS syndrome, it is in the context of extravascular overload, and membranoproliferative features and endothelial injury are seen rather than light chain deposition. 105, 106 Therapy for POEMS syndrome has not been well studied. If the lesions are in a limited area, radiation therapy (40-50 Gy) produces substantial improvement of clinical symptoms and signs in more than 50% of patients. For patients with widespread osteosclerotic lesions, treatment is similar to myeloma and depends on eligibility for stem cell transplantation. In eligible patients, autologous stem cell transplantation has provided significant responses; in one study all 14 evaluable patients achieved improvement or stabilization of neuropathy. 107 Supportive care, including aggressive physical and occupational therapy, is an important component of care.
